Press releases Archive - BioVariance - data-driven diagnostics

CIO Views honors Dr. Josef Scheiber as one of the most innovative executives in 2023

Sandra Bayreuther — Thu, 04 May 2023 10:43:26 +0000

CIO Views, a renowned trade publication for IT executives, has named Dr. Josef Scheiber, CEO of BioVariance GmbH, to its list of 10 Most Innovative Leaders to Follow in 2023. This award recognizes Scheiber’s groundbreaking work in the field of health data analytics, which has the potential to improve the lives of millions of people worldwide.

BioVariance GmbH is a German company specializing in the analysis of health data. The company aims to improve everyone’s health by providing personalized medical recommendations based on big data analytics. Using Big Data analytics and artificial intelligence, BioVariance develops personalized health plans based on each patient’s individual needs.

Dr. Josef Scheiber, BioVariance’s founder and CEO, has been instrumental in the company’s success. His years of experience in health research and data analytics have enabled him to update BioVariance’s technology and develop innovative approaches to improve people’s health.

The CIO Views award is further testament to the excellence of Dr. Josef Scheiber and BioVariance. In a statement, Scheiber said, “I am honored to be recognized by CIO Views as one of the Most Innovative Leaders of 2023. This award is a testament to the commitment and passion we have at BioVariance for improving the health and well-being of every individual. We will continue to work hard to push the boundaries of health research and data analytics and develop innovative solutions to improve the health of people around the world.”

Overall, the CIO Views award is a testament to the innovation and dedication of Dr. Josef Scheiber and BioVariance. With their groundbreaking work in the field of health data analytics, they have the potential to change the future of medicine and improve the lives of millions of people worldwide.

Der Beitrag CIO Views honors Dr. Josef Scheiber as one of the most innovative executives in 2023 erschien zuerst auf BioVariance - data-driven diagnostics.

BioVariance opens new offices and presents itself with a new logo

Sandra Bayreuther — Mon, 20 Mar 2023 14:09:33 +0000

BioVariance GmbH, a leading company for modern diagnostics in precision medicine, celebrated the opening of its new offices in Tirschenreuth on Friday, March 17, 2023. These are located in the former Meyer button factory, next to the Employment Agency, and offer a modern working environment with spacious offices flooded with light. Furthermore, a state-of-the-art laboratory around the basement is being planned. The move from Waldsassen to Tirschenreuth was made to support the growth of the company. “We are very proud that we now have spacious offices and will have modern laboratory space where our now 30-member team can work creatively and productively. We are also very pleased to be able to provide better service and support to our customers and partners in the region” said Dr. Josef Schreiber, Managing Director of BioVariance GmbH.

The opening marks an important milestone for BioVariance GmbH as it underscores the growth and expansion of the company, which aims to extend the human lifespan by simplifying the treatment of complex diseases. In the future, cancer, infectious, neurodegenerative and mental diseases should be as easy to treat as a normal cold.

The move is accompanied by a brand relaunch that emphasizes BioVariance’s commitment to improving people’s quality of life by better treating disease. Since its founding in 2013, the company has worked closely with the Bavarian Red Cross, diagnostic and pharmaceutical companies, universities and colleges, and various patient organizations to achieve this goal.

“We have worked hard to update our branding to ensure it reflects our commitment to improving human health,” said Dr. Josef Scheiber. “Our new brand image reflects our goal to make disease as treatable as the common cold. We look forward to working in our new facility and continuing our work to improve people’s quality of life.”

Der Beitrag BioVariance opens new offices and presents itself with a new logo erschien zuerst auf BioVariance - data-driven diagnostics.

Success at TOP 100: Ranga Yogeshwar honors BioVariance

Marco Vollath — Thu, 02 Dec 2021 16:14:09 +0000

Ranga Yogeshwar congratulated BioVariance GmbH from Waldsassen on its success in the TOP 100 innovation competition with a personal video on 26.11.2021. In addition, the science journalist recognized the achievements of this year’s TOP 100 companies at a joint online conference. The occasion was the TOP 100 final, which was originally planned as a face-to-face event. Ranga Yogeshwar is mentoring the innovation competition, which is being held for the 28th time. “True innovators are constantly changing, reinventing themselves and coming up with surprising solutions,” Yogeshwar said of the achievements of the TOP 100 companies. “During the Corona crisis, for example, they identified opportunities and came up with innovative processes in record time.” BioVariance was particularly impressive in the competition in the category “Innovation-promoting top management” in the size category up to 50 employees. The company’s innovation management is rated “A+” overall (on a scale of A to G). The “A” rating is awarded to companies that have unusually professional innovation management, even by international standards. Interdisciplinary work is also part of BioVariance’s innovation strategy. The team is composed of biologists, data analysts and software developers, among others, and aims to find innovative solutions for precision medicine in the healthcare, biotechnology and pharmaceutical sectors. In cooperation with physicians, the company monitors a patient’s molecular characteristics over a period of time to predict the efficacy, side effects and interactions of drugs and to determine the appropriate medication and dosage on an individual basis. Analysts develop cutting-edge technologies for oncologists and use scientific research to help them select the best possible therapies for their patients. “Regardless of which specialist area an employee belongs to at our company, we place a lot of value on everyone contributing and developing their ideas,” says Managing Director Dr. Josef Scheiber, explaining the company’s strategy. For larger projects, top management makes 25 percent of employees’ working time available. “Innovation successes set standards. And when everyone can contribute, it also strengthens motivation and cohesion among each other,” emphasizes Dr. Scheiber. “In this way, workflows are optimized and accelerated, so in the end, customers benefit as well.”

Click here for the complete company portraits: www.top100.de/die-top-innovatoren

TOP 100: The competition Since 1993, compamedia has been awarding the TOP 100 seal to medium-sized companies for special innovative strength and above-average innovative success. Since 2002, the scientific management has been in the hands of Prof. Dr. Nikolaus Franke. Franke is founder and director of the Institute for Entrepreneurship and Innovation at the Vienna University of Economics and Business. With 25 research awards and over 200 publications, he is one of the leading innovation researchers internationally. The mentor of TOP 100 is science journalist Ranga Yogeshwar. Project partners are the Fraunhofer Society for the Promotion of Applied Research and the BVMW association of small and medium-sized enterprises. The magazines manager magazin and impulse accompany the company comparison as media partners.

More info at www.top100.de. More information as well as general photo material on the TOP 100 competition can be found on the Internet at www.top100.de/presse or by sending an e-mail to presse@compamedia.de. Helen Schneider of BioVariance has more information on the award-winning company.

Contact Helen Schneider | Sales helen.schneider@biovariance.com Press release as download

Der Beitrag Success at TOP 100: Ranga Yogeshwar honors BioVariance erschien zuerst auf BioVariance - data-driven diagnostics.

BioVariance Lab successfully performs PCR pooling tests at schools

Marco Vollath — Tue, 08 Jun 2021 11:14:25 +0000

Waldsassen, 08.06.2021

In cooperation with the Administrative District Office, the Health Department, the BRK and some schools in the county of Tirschenreuth, the BioVariance laboratory recently started a pilot project for PCR testing of pupils and their teachers. A new gargle-method has been developed to enable soon the area-wide SARS-CoV-2 testing of all pupils twice a week. .

Here, the pupils gargle with a small amount of tap water at home and divide this sample fifty-fifty into two tubes. At school, the first half of the sample is then poured in a common cup for each class, the second tube is stored individually. This “pool” of several samples is tested for SARS-CoV-2 in the BioVariance laboratory using the established PCR method. The PCR is highly sensitive that even a single positive pupil can be detected in a pool of otherwise negative samples. If the pool result is positive, the corresponding school must be informed immediately. Then the second sample tubes of the class with the positive pool test are collected and tested individually by PCR on the same day to identify the positive person.

By now, eight schools are participating in this pilot project. More schools are supposed to follow in the next days and weeks. Further, the gargle method is currently also examined for the possible use in day-care centers.

Contact person

Helen Schneider | Sales and distribution

helen.schneider@biovariance.com

Press release for download

Der Beitrag BioVariance Lab successfully performs PCR pooling tests at schools erschien zuerst auf BioVariance - data-driven diagnostics.

BioVariance gains TOP 100 award

Marco Vollath — Wed, 10 Feb 2021 09:10:45 +0000

Waldsassen, 10.02.2021

BioVariance GmbH from Waldsassen gained the TOP 100 award 2021, which is given to highly innovative medium-sized companies once a year – now for the 28^th time. Before, BioVariance proved its innovative power in a scientific competition.

On behalf of compamedia, the organizer of the TOP 100 innovation competition, Prof. Dr. Nikolaus Franke and his team examined the innovative power of BioVariance based on 120 test criteria in 5 categories: innovation promoting management, innovative climate, innovative processes and organization, outward orientation / open innovation, and innovative success. The examination addresses the questions, whether innovation is the result of organized processes or a random product, that means the repeatability of innovative performances, and whether and how the corresponding solutions succeed on the market (more information about the test criteria on www.top100.de/pruefkriterien). Due to the current situation another category was included in the examination: the reaction of the company to the corona crisis.

BioVariance operates in the healthcare, biotechnology, and pharma sectors, where the company made its mark with the development of innovative AI solutions for precision medicine. In cooperation with physicians, BioVariance offers long-term monitoring of molecular changes in patients to predict the effectiveness, side effects and interactions of drugs, thereby determining the optimal medication and dosage. Furthermore, the company provides individual therapy recommendations for cancer patients based on patient’s genetic fingerprint. To achieve this, state-of-the-art automatization and parallelization techniques, machine learning, and mathematical algorithms are combined to analyze complex biomedical data.

„Innovative products and services develop in the mind when creativity and personal development are allowed and supported during the work process. We are glad to be one of the most innovative companies in Germany. This encourages us to keep breaking new grounds.” [Dr. Josef Scheiber, Managing Director of BioVariance]

BioVariance GmbH already ranked first in the Senetics Award category “Most innovative product idea or patent in healthcare” in 2018 and belonged to the “Top 20 Most innovative companies in the area of healthcare technology” according to Technology Innovators in 2019. Furthermore, in 2019, BioVariance was voted one of the most innovative companies of the year by brand eins for the third year in a row.

Prof. Dr. Nikolaus Franke, the scientific leader of TOP 100, is impressed by the awarded medium-sized companies: „The TOP 100 companies systematically concentrate on being highly innovative.”

On November 26^th, there is another reason to celebrate: All of this year’s TOP 100 award winners meet at the 7. German Mid-Tier Summit to receive congratulations from Ranga Yogeshwar. The science journalist has been acting as a mentor in the innovation competition for 10 years.

TOP 100: The competition

Compamedia has awarded the TOP 100 medium-sized companies with excellent innovative power and outstanding innovative success since 1993, with Prof. Dr. Nikolaus Franke being the scientific leader since 2002. Franke is the founder and chairman of the Institute for Entrepreneurship and Innovation at the University of Vienna. 25 gained scientific awards and over 200 publications make him one of the leading innovation researchers in the world. The mentor of TOP 100 is Ranga Yogeshwar. Project partners are the Fraunhofer Society for the Advancement of Applied Research and the German Association for Small and Medium-sized Businesses BVMW. The magazines manager magazin and impulse accompany the comparison of companies as a media partner. For more information and application visit www.top100.de.

Find more information and photo material regarding the TOP 100 competition on www.top100.de/presse, or send an email to presse@compamedia.de. More information about the awarded company can be obtained from Helen Schneider, BioVariance GmbH.

Contact person

Helen Schneider | Sales and Distribution

helen.schneider@biovariance.com

Press release for download

Der Beitrag BioVariance gains TOP 100 award erschien zuerst auf BioVariance - data-driven diagnostics.

TubeLab facilitates laboratory routine

Marco Vollath — Thu, 02 Jul 2020 06:26:34 +0000

Waldsassen – BioVariance finishes the development of TubeLab, a software for the organisation of multi-level laboratory processes. To ensure an effective performance of the workflow, TubeLab was developed in cooperation with a renowned diagnostics laboratory. In this lab, TubeLab also expedites SARS-CoV-2 coronavirus tests under the name of COVIDetect. Thus, hundreds of patient samples can be processed quickly, safely and trackably every day. We at BioVariance GmbH are proud to contribute to the containment of the pandemic.

What are TubeLab’s features?

TubeLab digitalizes sample handling and tracking, process tracking as well as the evaluation of signals and quality. As a result, the overall duration of the coronavirus test workflow – from sample scan to the transmission of results – can be reduced significantly.

The software visualizes every work step in real time and thus documents who executes a certain work step at a certain time. Furthermore, TubeLab validates thresholds by request and informs the user when, for example, the quality control fails the predefined criteria (see Fig.1 ). These features allow a quick and safe processing and facilitate the organisation and control of the workflow.

Another fundamental benefit is TubeLab’s intuitive operability and flexibility. The software can be installed on every lab-own server with a granted access to the intranet. Besides, the high scalability allows the processing of an unlimited amount of data. Data protection is guaranteed in every single work step. Thus, large amounts of data can be processed, stored and transmitted in a safe and fast manner.

Fig. 1: Automated threshold monitoring with TubeLab.

Advantages of TubeLab:

user-friendly interface
workflow visualization in real time
transparent and trackable work process
smooth change of shifts and responsibilities
automated threshold validation
scalable system to process large amounts of data

Contact person
Helen Rießbeck | Sales and Distribution
E-Mail: helen.riessbeck @biovariance.com

Press release for download

Der Beitrag TubeLab facilitates laboratory routine erschien zuerst auf BioVariance - data-driven diagnostics.

OncoVariant automates the drug search for oncologists

Marco Vollath — Tue, 30 Jun 2020 13:13:00 +0000

Waldsassen – BioVariance has finished the development of the platform OncoVariant for the interpretation of genetic variants in cancer patients. Thereby, the crucial search for suitable drugs is simplified and accelerated significantly.

„Using OncoVariant, the oncologist is able to find the best and personalized therapy for each patient way faster than before.” [Dr. Josef Scheiber, Founder and CEO of BioVariance]

Nowadays, the manual search for the optimal medication is still a labor-intensive and time-consuming process for oncologists. Every patient and tumor shows different reactions to drugs due to individual genetic conditions. At the same time, the amount of data the physician has to examine has grown exponentially in the last years, resulting in a higher expenditure of time and work.

At this point, BioVariance offers state-of-the-art automatization and parallelization techniques: The web-based and user-friendly application OncoVariant enables the oncologist to consult the worldwide existing literature for the selection of the optimal treatment. All publicly available databases containing information about gene-drug correlations are included in the query. Patient’s genetic variations are automatically compared to the profound knowledge in these databases to identify individual treatment options.

The oncologist receives a final report with a summary of all information found by OncoVariant. This report shows which genetic variants have to be considered for the treatment of the cancer patient and which medication promises the greatest success for this patient.

Here you will receive an impression of the user-friendly platform OncoVariant.

Contact person
Helen Rießbeck | Sales and Distribution
E-Mail: helen.riessbeck @biovariance.com
Press release for download

Der Beitrag OncoVariant automates the drug search for oncologists erschien zuerst auf BioVariance - data-driven diagnostics.

HORIZON 2020 – REVERT

Marco Vollath — Mon, 17 Feb 2020 07:46:19 +0000

Waldsassen – BioVariance has received a commitment for the project REVERT from the European Commission as part of HORIZON 2020, the EU framework program for research and innovation. The project goal is to identify the most effective and cost-efficient therapies for patients suffering from inoperable and metastatic colorectal cancer. The project involves 14 multidisciplinary partners from 6 European countries. Physicians (primarily oncologists), biologists, software developers and data analysts will collaborate closely (see Fig. 1) for a better understanding and treatment of the various types of colorectal cancer. With approximately 1,8 million new cases in 2018, colorectal cancer is the third most common tumor type worldwide. In Germany, where Biovariance is headquartered, it is the third most common cancer type amongst men and ranks second amongst women.

Fig. 1: HORIZON 2020 Team – collaborates closely for the EU Project REVERT

BioVariance will develop an artificial intelligence platform to predict the most promising therapy option for each cancer patient individually. To achieve this, molecular data such as tumor genetics will be analyzed from patients that have already been treated. Using AI and Machine Learning, correlations between biomarker data points and the effectiveness of specific drug compounds can be identified. Genetic data of newly diagnosed patients will also be compared with patients showing similar clinical profiles. By implementing specialized prediction models, newly diagnosed patients can be optimally treated based on the most current findings.

Project coordinator is San Raffaele S.p.A. in Rome, a market leader in the field of health protection, scientific research and care. The total investment will be approx. 6 million Euro, including 250.000 Euro for the development of the AI platform by BioVariance. The project is scheduled to commence in January 2020 with a duration of 4 years.

Contact person
Evgenija Melnik | Marketing
E-Mail: evgenija.melnik@biovariance.com
Press release for download

Der Beitrag HORIZON 2020 – REVERT erschien zuerst auf BioVariance - data-driven diagnostics.

For the research of DIPG across 14 countries

Marco Vollath — Fri, 23 Aug 2019 09:48:04 +0000

DIPG (diffuse intrinsic pontine glioma) describes a brain tumor in children for which there exists no cure or positive life-changing treatment. Even if this type of pontine glioma can be classified as “rare diseases”, it is the most common deadly brain tumor in children aged 4 to 9 years. Less than 1% of children diagnosed with DIPG survive the next five years.

These facts highlight the importance of research on effective treatments for DIPG to identify the best treatment. Therefor, the Foundation for Innovative Medicine in Munich focuses on the research and prevention of brain tumors in children.

Fig. 1: The team of BioVariance with Christian Bernhard and son (in front)

The honorary team is supported by numerous private initiatives that collect donations for this important research. Christian Bernhard and son son have also set themselves the task of doing something against this “monster” called DIPG. Participating in the “Balkan Express 2019” and collecting donations for this initiative should raise awareness for this serious disease and encourage research for an effective treatment.

BioVariance GmbH from Waldsassen is also very pleased to support the Bernhard family in their project. The company, founded in 2013, focuses on individual therapy recommendations – especially in the field of oncology. Through further awareness and research of this disease, you can also support personalized treatments.

The “Balkan Express” started on 22.08.2019 and lasts in total 13 days. In this race the participants have to travel through 14 countries. The conditions: the car must be older than 20 years and the use of a navigation device is forbidden. If you want to join them on this adventurous journey, you can do it here. You also want to support the research? A donation account has been set up at betterplace.org.

You need further information on DIPG? We wish both guys success!

Contact person:

Kristina Schraml

Email: kristina.schraml@biovariance.com

Presse release for download

Der Beitrag For the research of DIPG across 14 countries erschien zuerst auf BioVariance - data-driven diagnostics.

BioVariance GmbH is again one of the most innovative companies in Germany

Marco Vollath — Thu, 28 Feb 2019 11:08:04 +0000

Waldsassen – The statistic portal Statista and the business magazine „brand eins Innovation ist…“ have honored Germany’s most innovative companies for the fourth time. BioVariance GmbH was once again able to assert itself in the category of chemicals, pharmaceuticals and biotechnology (fewer than 250 employees). For the third year in a row, BioVariance GmbH is one of the 16 most innovative companies in Germany in this category.

Dr. Josef Scheiber, Managing Director: “We are very pleased that we were chosen again as one of the most innovative companies in Germany. This encourages us to keep on breaking new grounds.”

About the ranking

For this year’s ranking, more than 2,500 company representatives, 400 experts from the Berlin Institute for Innovation and Technology (iit) and more than 20,000 executives from the Statista expert panel “Expert Circle” selected 542 highly innovative companies from thousands of enterprises in 20 sectors. Only companies with a head office or a branch in Germany could be awarded as “Innovator of the Year 2019”.

Contact person
Evgenija Melnik | Marketing
E-Mail: evgenija.melnik@biovariance.com
Press release for download

Der Beitrag BioVariance GmbH is again one of the most innovative companies in Germany erschien zuerst auf BioVariance - data-driven diagnostics.